These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 34716911)

  • 21. Liver and Cardiovascular Damage in Patients With Lean Nonalcoholic Fatty Liver Disease, and Association With Visceral Obesity.
    Fracanzani AL; Petta S; Lombardi R; Pisano G; Russello M; Consonni D; Di Marco V; Cammà C; Mensi L; Dongiovanni P; Valenti L; Craxì A; Fargion S
    Clin Gastroenterol Hepatol; 2017 Oct; 15(10):1604-1611.e1. PubMed ID: 28554682
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Estimating steatosis and fibrosis: Comparison of acoustic structure quantification with established techniques.
    Karlas T; Berger J; Garnov N; Lindner F; Busse H; Linder N; Schaudinn A; Relke B; Chakaroun R; Tröltzsch M; Wiegand J; Keim V
    World J Gastroenterol; 2015 Apr; 21(16):4894-902. PubMed ID: 25945002
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Non-Alcoholic Fatty Liver Disease Treatment in Patients with Type 2 Diabetes Mellitus; New Kids on the Block.
    Athyros VG; Polyzos SA; Kountouras J; Katsiki N; Anagnostis P; Doumas M; Mantzoros CS
    Curr Vasc Pharmacol; 2020; 18(2):172-181. PubMed ID: 30961499
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Association between non-alcoholic fatty liver disease and bone turnover biomarkers in post-menopausal women with type 2 diabetes.
    Mantovani A; Sani E; Fassio A; Colecchia A; Viapiana O; Gatti D; Idolazzi L; Rossini M; Salvagno G; Lippi G; Zoppini G; Byrne CD; Bonora E; Targher G
    Diabetes Metab; 2019 Sep; 45(4):347-355. PubMed ID: 30315891
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Advanced glycation end product: A potential biomarker for risk stratification of non-alcoholic fatty liver disease in ELSA-Brasil study.
    Pereira ENGDS; Paula DP; de Araujo BP; da Fonseca MJM; Diniz MFHS; Daliry A; Griep RH
    World J Gastroenterol; 2021 Aug; 27(29):4913-4928. PubMed ID: 34447235
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prevalence of advanced liver fibrosis and steatosis in type-2 diabetics with normal transaminases: A prospective cohort study.
    Makker J; Tariq H; Kumar K; Ravi M; Shaikh DH; Leung V; Hayat U; Hassan MT; Patel H; Nayudu S; Chilimuri S
    World J Gastroenterol; 2021 Feb; 27(6):523-533. PubMed ID: 33642826
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Interest of hepatic steatosis index (HSI) in screening for metabolic steatopathy in patients with type 2 diabetes.
    Fennoun H; Mansouri SE; Tahiri M; Haraj NE; Aziz SE; Hadad F; Hliwa W; Badr W; Chadli A
    Pan Afr Med J; 2020; 37():270. PubMed ID: 33598084
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bedside ultrasound in the diagnosis of nonalcoholic fatty liver disease.
    Khov N; Sharma A; Riley TR
    World J Gastroenterol; 2014 Jun; 20(22):6821-5. PubMed ID: 24944472
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Serum levels of soluble dipeptidyl peptidase-4 in type 2 diabetes are associated with severity of liver fibrosis evaluated by transient elastography (FibroScan) and the FAST (FibroScan-AST) score, a novel index of non-alcoholic steatohepatitis with significant fibrosis.
    Sagara M; Iijima T; Kase M; Kato K; Sakurai S; Tomaru T; Jojima T; Usui I; Aso Y
    J Diabetes Complications; 2021 May; 35(5):107885. PubMed ID: 33602617
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Association of leptin with severity of non-alcoholic fatty liver disease: A population-based study.
    Rotundo L; Persaud A; Feurdean M; Ahlawat S; Kim HS
    Clin Mol Hepatol; 2018 Dec; 24(4):392-401. PubMed ID: 30068065
    [TBL] [Abstract][Full Text] [Related]  

  • 31. MR elastography is effective for the non-invasive evaluation of fibrosis and necroinflammatory activity in patients with nonalcoholic fatty liver disease.
    Costa-Silva L; Ferolla SM; Lima AS; Vidigal PVT; Ferrari TCA
    Eur J Radiol; 2018 Jan; 98():82-89. PubMed ID: 29279175
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of Empagliflozin on Liver Steatosis and Fibrosis in Patients With Non-Alcoholic Fatty Liver Disease Without Diabetes: A Randomized, Double-Blind, Placebo-Controlled Trial.
    Taheri H; Malek M; Ismail-Beigi F; Zamani F; Sohrabi M; Reza Babaei M; Khamseh ME
    Adv Ther; 2020 Nov; 37(11):4697-4708. PubMed ID: 32975679
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Moderate alcohol consumption is associated with advanced fibrosis in non-alcoholic fatty liver disease and shows a synergistic effect with type 2 diabetes mellitus.
    Blomdahl J; Nasr P; Ekstedt M; Kechagias S
    Metabolism; 2021 Feb; 115():154439. PubMed ID: 33246008
    [TBL] [Abstract][Full Text] [Related]  

  • 34. US-FLI score - Is it possible to predict the steatosis grade with an ultrasonographic score?
    Xavier SA; Monteiro SO; Arieira CM; Castro FD; Magalhães JT; Leite SM; Marinho CM; Cotter JB
    Mol Genet Metab; 2021 Mar; 132(3):204-209. PubMed ID: 33558081
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Diabetes impacts prediction of cirrhosis and prognosis by non-invasive fibrosis models in non-alcoholic fatty liver disease.
    Bertot LC; Jeffrey GP; de Boer B; MacQuillan G; Garas G; Chin J; Huang Y; Adams LA
    Liver Int; 2018 Oct; 38(10):1793-1802. PubMed ID: 29575516
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Association of 1-deoxy-sphingolipids with steatosis but not steatohepatitis nor fibrosis in non-alcoholic fatty liver disease.
    Weyler J; Verrijken A; Hornemann T; Vonghia L; Dirinck E; von Eckardstein A; Vanwolleghem T; Michielsen P; Peiffer F; Driessen A; Hubens G; Staels B; Francque S; Van Gaal L
    Acta Diabetol; 2021 Mar; 58(3):319-327. PubMed ID: 33084982
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical utility of noninvasive scores in assessing advanced hepatic fibrosis in patients with type 2 diabetes mellitus: a study in biopsy-proven non-alcoholic fatty liver disease.
    Alkayyali T; Qutranji L; Kaya E; Bakir A; Yilmaz Y
    Acta Diabetol; 2020 May; 57(5):613-618. PubMed ID: 31897769
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Utility of transient elastography (fibroscan) and impact of bariatric surgery on nonalcoholic fatty liver disease (NAFLD) in morbidly obese patients.
    Garg H; Aggarwal S; Shalimar ; Yadav R; Datta Gupta S; Agarwal L; Agarwal S
    Surg Obes Relat Dis; 2018 Jan; 14(1):81-91. PubMed ID: 29126863
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Triglyceride glucose-waist to height ratio: a novel and effective marker for identifying hepatic steatosis in individuals with type 2 diabetes mellitus.
    Malek M; Khamseh ME; Chehrehgosha H; Nobarani S; Alaei-Shahmiri F
    Endocrine; 2021 Dec; 74(3):538-545. PubMed ID: 34355342
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Noninvasive assessment of hepatic steatosis and fibrosis in patients with severe obesity.
    Coccia F; Testa M; Guarisco G; Bonci E; Di Cristofano C; Silecchia G; Leonetti F; Gastaldelli A; Capoccia D
    Endocrine; 2020 Mar; 67(3):569-578. PubMed ID: 31858390
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.